XML 18 R7.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Operating activities:    
Net income (loss) $ 80,873 $ (67,381)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation 6,253 4,858
Amortization of right-of-use operating lease assets 1,035 0
Amortization of patents 948 895
Amortization of premium (discount) on investments, net (5,163) 1,845
Amortization of debt issuance costs 957 853
Amortization of convertible senior notes discount 17,661 16,364
Stock-based compensation expense 87,437 62,327
Non-cash losses related to patents, licensing and property, plant and equipment 203 415
Provision for deferred income taxes 14,436 0
Changes in operating assets and liabilities:    
Contracts receivable (16,255) 46,193
Inventories (5,736) 915
Other current and long-term assets (6,372) (5,177)
Accounts payable (16,104) (14,239)
Accrued compensation (9,219) (10,062)
Accrued liabilities and deferred rent 3,283 (8,218)
Deferred contract revenue (73,643) 483,814
Net cash provided by operating activities 80,594 513,402
Investing activities:    
Purchases of short-term investments (1,049,274) (648,902)
Proceeds from short-term investments 877,966 364,048
Purchases of property, plant and equipment (7,243) (8,977)
Acquisition of licenses and other assets, net (2,310) (1,854)
Net cash used in investing activities (180,861) (295,685)
Financing activities:    
Proceeds from equity awards 102,004 10,178
Payments of tax withholdings related to vesting of employee stock awards (8,034) 0
Proceeds from the issuance of common stock to Biogen 0 447,965
Net cash provided by financing activities 93,970 458,143
Net increase in cash and cash equivalents (6,297) 675,860
Cash and cash equivalents at beginning of period 278,820 129,630
Cash and cash equivalents at end of period 272,523 805,490
Supplemental disclosures of cash flow information:    
Interest paid 4,776 4,753
Supplemental disclosures of non-cash investing and financing activities:    
Right-of-use assets obtained in exchange for lease obligations 13,920 0
Amounts accrued for capital and patent expenditures $ 3,073 $ 2,645